Elevance Health, Inc. (NYSE:ELV) President and CEO Gail Boudreaux has sold shares of the company's common stock, with transactions totaling over $17 million. The sales took place on July 22, 2024, and were executed in multiple trades with prices ranging from $498.50 to $504.27 per share.
The sequence of sales reported by Boudreaux indicates a strategic divestment of Elevance Health shares, with the first transaction involving 1,100 shares at $498.50 each. Subsequent sales saw larger quantities being sold, including a batch of 20,779 shares at an average price of $500.36, and another of 6,621 shares averaging $501.40 per share. The largest single transaction price reported was for a batch of 2,250 shares at $504.27 each.
In total, these transactions represent a significant movement in Elevance Health's stock by one of its top executives. Following the sales, Boudreaux still holds a substantial number of shares in the company, indicating continued vested interest in the company's performance.
Investors and stakeholders often monitor such sales as indicators of an executive’s perspective on the company's future prospects. It's worth noting that the sales were made in accordance with a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to establish predetermined trading plans for selling stocks at a time when they are not in possession of material non-public information.
The Rule 10b5-1 plan in question was adopted by Boudreaux on April 19, 2024, suggesting that the sales were planned well in advance and not in response to any immediate market or internal company developments.
Elevance Health, formerly known as Anthem, Inc., is a major player in the healthcare plans industry, and such transactions by top executives are closely watched for insights into the company's internal dynamics and market positioning.
As of the latest filings, the exact distribution of the sale prices for the shares sold by Boudreaux has been provided under the SEC's full disclosure requirements, ensuring transparency for all market participants.
In other recent news, Elevance Health Inc. reported a robust Q2 performance with operating revenue of $43.22 billion and an adjusted EPS of $10.12, surpassing estimates. The company also expanded its primary care services through a strategic partnership with the private equity firm Clayton, Dubilier & Rice. However, TD Cowen lowered its Elevance shares target to $589 from $624, citing concerns about a rise in Medicaid utilization for the second half of 2024. Despite the reduced price target, TD Cowen reaffirmed a Buy rating for Elevance. Baird also adjusted its price target for Elevance, reducing it to $625 from $649, citing near-term headwinds but suggesting these present an attractive buying opportunity given the company's long-term prospects. RBC Capital upgraded its price target for Elevance to $585, maintaining an Outperform rating, while BofA Securities downgraded the stock rating to Neutral due to Medicaid margin concerns. Truist Securities reiterated a Buy rating, expressing confidence in the company's financial preparedness, and Morgan Stanley maintained an Overweight rating with a price target of $643. These are all recent developments in the company's financial landscape.
InvestingPro Insights
Elevance Health, Inc. (NYSE:ELV) has recently seen a significant transaction from its President and CEO, which may lead investors to look more closely at the company's financial health and market performance. InvestingPro data shows a market capitalization of 116.56 billion USD, indicating the substantial size and influence of Elevance Health in the healthcare sector. With a P/E ratio of 17.65, the company is trading at a multiple that suggests investors are expecting earnings growth, albeit the P/E ratio adjusted for the last twelve months as of Q2 2024 is slightly lower at 15.78, which may reflect the company's earnings performance relative to its share price.
The company's dividend yield as of the latest data point stands at 1.29%, and Elevance Health has demonstrated a commitment to returning value to shareholders by raising its dividend for 14 consecutive years, an InvestingPro Tip that underscores its financial stability and appeal to income-focused investors. Furthermore, the company's stock has experienced a dip over the last week, with a 1-week price total return of -8.9%, which may attract investors looking for a potential entry point in anticipation of a rebound.
For those considering a deeper dive into Elevance Health's stock, there are additional InvestingPro Tips available that could provide further insights into the company's operations and market outlook. For instance, Elevance Health is a prominent player in the Healthcare Providers & Services industry and operates with a moderate level of debt, ensuring it has a solid standing in its sector. There are 12 more InvestingPro Tips available, which can be accessed through the InvestingPro platform, offering valuable information for making informed investment decisions. Interested readers can use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription for more detailed analysis and tips.
As the company navigates the market, these financial metrics and insights can help investors understand Elevance Health's current position and future potential, especially in light of recent insider trading activity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.